Palvella Therapeutics

PVLA

Market cap $1.88B

Physician and seasoned life sciences investor with more than two decades of experience across clinical practice, biotechnology investing, and board leadership

Mr. Taylor brings a strong track record launching multiple high-profile therapies, most recently serving as Senior Vice President, Sales at Arcutis Biotherapeutics (Nasdaq: ARQT), where he led U.S. sales efforts for ZORYVE®, a next-generation topical PDE4 inhibitor; previously, he held leadership roles at Incyte (Nasdaq: INCY) supporting the launch of OPZELURA®

New Drug Application (NDA) for QTORIN™ rapamycin for the treatment of microcystic lymphatic malformations (microcystic LMs) on track for planned submission in second half of 2026

Review delineates differences in clinical strategies between microcystic and macrocystic lymphatic malformations to guide disease-specific clinical trial design and treatment approaches Manuscript emphasizes the importance of early therapeutic intervention in children to help reduce the risk of more serious complications over time Review supports the scientific rationale of QTORIN™ 3.9% rapamycin anhydrous gel as a potential targeted therapy for microcystic lymphatic malformations WAYNE, Pa., March 30, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or “the Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced the publication of a comprehensive review article in the Journal of Vascular Anomalies (JoVA) titled “Microcystic and Macrocystic Lymphatic Malformations: Distinct Genetics and Clinical Strategies.

Poster #76954 highlights QTORIN™ rapamycin's single phase anhydrous gel formulation designed to optimize dermal bioavailability of rapamycin for mTOR-driven skin diseases while overcoming the crystallization, stability, and dermal penetration challenges posed by rapamycin

An executive at Palvella Therapeutics reported selling 4,302 common shares for approximately $508,000 on March 18, 2026. The disposal resulted from the immediate sale of shares acquired through option exercise.

Jenkins acquired 4,000 shares in the underwritten public offering of Palvella Therapeutics at $125.00 per share (~$500,000 total value) on Feb. 27, 2026. Jenkins' directly held shares after the transaction totaled 187,171; total direct plus indirect holdings were 200,687.

WAYNE, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (“Palvella” or “the Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that the Company will report its full year 2025 financial results before market open on Tuesday, March 31, 2026. Palvella management will host a conference call for investors at 8:30 a.m. ET on that same day to discuss the results and provide a corporate update.

Ms. McDonough previously served as Senior Vice President of Patient Access, Analytics, and Operations at Krystal Biotech (Nasdaq: KRYS), where she helped lead the U.S. launch of VYJUVEK®, supporting its growth from FDA approval in 2023 to $389 million in annual sales in 2025

Palvella Therapeutics is positioned as a cautious Buy, driven by strong Phase 3 data for QTORIN rapamycin in microcystic lymphatic malformations (mLM). QTORIN's clinical profile demonstrates high efficacy and a benign safety profile, addressing a major unmet need in mLM and offering first-mover advantage in a niche orphan market. PVLA's mLM program alone could justify a multibillion-dollar valuation, with cVM label expansion potentially doubling revenue opportunity; current cash runway extends well beyond regulatory milestones.